title: Lanthanum carbonate (Shire).
abstract: Shire Pharmaceuticals Group plc, under exclusive license from AnorMED Inc (a subsidiary of Johnson Matthey), is developing lanthanum carbonate, a phosphate-binding lanthanum salt, for the potential treatment of hyperphosphatemia in dialysis patients. It is currently in pre-registration in the US, Canada and Western Europe, and earlier stage clinical trials are ongoing in Japan.
authors.affiliation: A Manzoni Hospital, Department of Nephrology and Dialysis, Via Dell'Eremo 9-11, 23900 Lecco (Lc), Italy. nefrologia@ospedale.lecco.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Locatelli
authors.forename: Marco
authors.initials: M
authors.lastname: D'Amico
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pontoriero
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007811:Lanthanum / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010710:Phosphates / Q000378:metabolism / Q000652:urine; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
chemical_list: D010710:Phosphates; C119467:lanthanum carbonate; D007811:Lanthanum